Posted by Michael Wonder on 04 Feb 2021
Bayer receives approval for Nubeqa in China for the treatment of men with non-metastatic castration-resistant prostate cancer
3 February 2021 - The Chinese National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease.
Nubeqa has already received regulatory approval in several other markets around the world, including the U.S., the European Union, Brazil, Canada and Japan.
